Back to GSKView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Depressive Disorder and Anxiety Disorders
View Full LandscapeDrug Information
Target Indication
Depressive Disorder and Anxiety Disorders
Clinical Trial
NCT00343707Last updated: 1/23/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
FluoridePhase 3
Dental Caries
Combined Hepatitis A and B vaccinePhase 3
Hepatitis B
62.5/25mcgPhase 3
Pulmonary Disease, Chronic Obstructive
Losmapimod 7.5 mg twice dailyPhase 3
Acute Coronary Syndrome
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3
Infections, Meningococcal
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts